ATRA - Atara Biotherapeutics, Inc.

QQQ $ 612.11 $ 7.61 (1.26 %)

DIA $ 467.12 $ 5.24 (1.13 %)

SPY $ 671.75 $ 6.91 (1.04 %)

TLT $ 91.68 $ 0.35 (0.38 %)

GLD $ 401.36 $ 14.16 (3.64 %)

Previous Close

$ 16.04

Open

$ 15.08

Bid

$ 14.01 x 50

Ask

$ 16.80 x 27

Day's Range

$ 14.95 - $ 16.09

52 Week Range

$ 5.01 - $ 18.71

Volume

76,768

Average Volume

Market Cap

112.65M

Beta (5Y Monthly)

$ 1.55

PE Ratio (TTM)

$ 19.44

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-11-2025	06-30-2025	10-Q
2	05-15-2025	03-31-2025	10-Q
3	03-07-2025	01-01-1970	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-12-2024	06-30-2024	10-Q
6	05-09-2024	03-31-2024	10-Q
7	03-28-2024	12-31-2023	10-K
8	11-01-2023	09-30-2023	10-Q
9	08-08-2023	06-30-2023	10-Q
10	05-08-2023	03-31-2023	10-Q
11	02-08-2023	12-31-2022	10-K
12	11-08-2022	09-30-2022	10-Q
13	08-08-2022	06-30-2022	10-Q
14	05-05-2022	03-31-2022	10-Q
15	02-28-2022	12-31-2021	10-K
16	11-04-2021	09-30-2021	10-Q
17	08-09-2021	06-30-2021	10-Q
18	05-04-2021	03-31-2021	10-Q
19	03-01-2021	12-31-2020	10-K
20	11-09-2020	09-30-2020	10-Q
21	08-05-2020	06-30-2020	10-Q
22	05-06-2020	03-31-2020	10-Q
23	02-27-2020	12-31-2019	10-K
24	11-07-2019	09-30-2019	10-Q
25	08-08-2019	06-30-2019	10-Q
26	05-09-2019	03-31-2019	10-Q
27	02-26-2019	12-31-2018	10-K
28	11-06-2018	09-30-2018	10-Q
29	08-01-2018	06-30-2018	10-Q
30	05-08-2018	03-31-2018	10-Q
31	02-27-2018	12-31-2017	10-K
32	11-09-2017	09-30-2017	10-Q
33	08-07-2017	06-30-2017	10-Q
34	05-04-2017	03-31-2017	10-Q
35	03-09-2017	12-31-2016	10-K
36	11-04-2016	09-30-2016	10-Q
37	08-08-2016	06-30-2016	10-Q
38	05-06-2016	03-31-2016	10-Q
39	03-04-2016	12-31-2015	10-K
40	11-06-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12 Health Care Stocks Moving In Friday's A...
10/17/2025 21:07:13

4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals

4 Biotechnology Stocks That Outshine In Mo...
09/29/2025 11:11:04

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...

Atara Biotherapeutics' Greg Ciongoli To As...
09/03/2025 22:03:16

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus...

Atara Biotherapeutics Says Co Has Resumed ...
08/11/2025 20:30:32

Atara Biotherapeutics Q2 EPS $0.19 Beats $...
08/11/2025 20:13:10

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of...

Atara Biotherapeutics Says FDA Accepts Fil...
07/24/2025 12:20:13

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026If Approved, Tab-cel Would Be First Approved Thera...

Pierre Fabre Pharma Announces Transfer Of ...
07/15/2025 12:19:01

Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical programEnr...

Atara Biotherapeutics Resubmits Tabelecleu...
07/14/2025 12:01:03

12 Health Care Stocks Moving In Wednesday'...
06/18/2025 21:05:53

Atara Biotherapeutics Q1 EPS $3.50 Beats $...
05/15/2025 13:17:07

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of...

Atara Biotherapeutics Prices Offering Of 8...
05/15/2025 12:36:02

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus...

12 Health Care Stocks Moving In Tuesday's ...
05/06/2025 12:08:25

Atara Biotherapeutics Provides Regulatory ...
05/05/2025 21:20:46

FDA lifts clinical hold enabling resumption of clinical trialsFDA has granted a Type A Meeting to discuss path forward for BLAA...

12 Health Care Stocks Moving In Thursday's...
04/24/2025 12:06:59

Atara Biotherapeutics Transfers Full Manuf...
04/04/2025 20:36:39

On March 31, 2025, Atara Biotherapeutics, Inc., (the "Company") entered into an Amendment (the "Amendment") to ...

Canaccord Genuity Maintains Buy on Atara B...
03/11/2025 13:08:34

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $17 price target.

Atara Biotherapeutics Q4 2024 GAAP EPS $(1...
03/07/2025 21:03:45

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of...

HC Wainwright & Co. Reiterates Neutral on ...
01/28/2025 12:09:30

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.

HC Wainwright & Co. Reiterates Neutral on ...
01/22/2025 12:51:22

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.

fda-places-clinical-hold-on-atara-biotherapeutics-two-cell-therapy-programs

FDA Places Clinical Hold On Atara Biothera...
01/21/2025 18:11:23

FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre ...